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Introduction: Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) are present in some neuromyelitis
optica patients who lack antibodies against aquaporin-4 (AQP4-IgG). The effects of neuromyelitis optica MOG-IgG in
the central nervous system have not been investigated in vivo. We microinjected MOG-IgG, obtained from patients
with neuromyelitis optica, into mouse brains and compared the results with AQP4-IgG.
Results: MOG-IgG caused myelin changes and altered the expression of axonal proteins that are essential for action
potential firing, but did not produce inflammation, axonal loss, neuronal or astrocyte death. These changes were
independent of complement and recovered within two weeks. By contrast, AQP4-IgG produced complement-mediated
myelin loss, neuronal and astrocyte death with limited recovery at two weeks.
Conclusions: These differences mirror the better outcomes for MOG-IgG compared with AQP4-IgG patients and raise
the possibility that MOG-IgG contributes to pathology in some neuromyelitis optica patients.
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Most neuromyelitis optica (NMO) patients have IgG
against aquaporin-4 (AQP4), here termed AQP4-IgG
[1,2]. AQP4 is a water channel protein found in astro-
cytes throughout the central nervous system (CNS), es-
pecially in perivascular astrocyte foot processes [3]. In
cultured cells, AQP4-IgG binds extracellular conform-
ational domains of AQP4 and activates complement,
causing cell lysis [4]. In mice, intracerebral injection of
AQP4-IgG activates co-injected human complement
(Chu) and damages the astrocytes [5,6]. Inflammatory
cells then enter the lesion causing further tissue injury
including demyelination and axonal damage. In AQP4-
IgG NMO patients, recovery after an attack is usually
limited [7-9].
A few NMO patients without AQP4-IgG have IgG
against myelin oligodendrocyte glycoprotein (MOG-IgG),
which recognize extracellular conformational domains of
MOG [10-13]. MOG is expressed on the outer surface of
CNS myelin sheaths and comprises about 0.05% of total* Correspondence: mpapadop@sgul.ac.uk
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MOG-IgG NMO has more favorable clinical outcome
than AQP4-IgG NMO, with resolution of imaging abnor-
malities [10,11,15,16]. It is currently unclear whether
MOG-IgG plays any role in NMO by causing lesions in
the CNS in vivo. Here we compared the effects of MOG-
IgG with those of AQP4-IgG in the intracerebral injection
mouse model. We used total IgG from a normal subject
(IgGCON) and from NMO patients with AQP4-IgG
(IgGAQP4) or MOG-IgG (IgGMOG).
Materials and methods
IgG and complement
NMO patients with MOG-IgG or AQP4-IgG were identi-
fied using live cell-based assays. Briefly, AQP4-IgG and
MOG-IgG positivity was determined by visualization of
binding to human embryonic kidney cells, transfected with
the extracellular and trans-membrane domains of MOG or
with full-length M23-AQP4. Details of the assays are given
elsewhere [5,10,11,15]. IgG was purified using Protein G
from sera or plasmas of five patients with AQP4-IgG
NMO, five MOG-IgG NMO or one healthy volunteer. The
effect of injecting IgG and Chu from healthy volunteers into
mouse brain was extensively investigated in our earlieral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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IgG preparations (6 – 38 mg/ml) are termed IgGAQP4,
IgGMOG and IgGCON. Clinical details of the 5 AQP4-IgG +
[5] and 5 MOG-IgG+ [11,15] patients are given elsewhere.
To deplete MOG-IgG, the IgGMOG was adsorbed by in-
cubation with MOG-HEK cells until MOG-IgG became
undetectable (IgGMOG(AdsMOG-HEK)). IgGMOG adsorbed
against untransfected HEK cells (IgGMOG(AdsHEK)) was
used as control. A chimeric mouse-human recombinant
monoclonal anti-mouse MOG antibody, MOG-IgG2B7,
was produced as described [19]. Human recombinant
monoclonal anti-AQP4 IgG1, termed AQP4-IgG53, was
also generated [20]. A measles virus-specific antibody
termed CON-IgG2B4 was used as isotype control [20].
The source of Chu was fresh serum from healthy
volunteers [5].
Mice
Experiments were performed at St. George’s, University of
London using CD1 mice 8 – 12 30 – 35 g, 8 – 12w old.
Protocols were approved by the British Home Office
(Project Licence, PPL 70/7081). After administering 2,2,2-
tribromoethanol i.p., mice were mounted onto a stereotac-
tic frame (Benchmark, Neurolab, St Louis, MO, USA).
Four burrholes were made on the right side using a high
speed drill (0.7 mm burr, Foredom, Bethel, CT, USA) at
the following coordinates in millimetres from the bregma
(lateral, anterior): (1, 0), (1, −1), (1, −2), (2, −1). Mice were
allocated to the different experimental groups by a person
unaware of the aim of the study. A 30 g needle attached to
50 ml gas-tight glass syringe (Hamilton, Reno, NV, USA)
was inserted 3 mm deep to micro-infuse (1 μL/min) into
the right hemisphere 16.8 μL IgGMOG, IgGAQP4 or IgGCON
or 16.8 μL (20 μg) MOG-IgG2B7 or AQP4-IgG53 + 11.2 μL
Chu (or normal saline) as described [5]. Rectal temperature
was kept 37 – 38°C with a heating lamp. After regaining
the righting reflex, mice were returned to their cages, kept
in 12 hour light/dark cycle and given water and normal
chow ad libitum. Mice (5 per group) were killed at
24 hours, seven days or two weeks. Investigators were un-
aware of which antibody was injected.
Mouse brain histology and immunohistology
Mice were anaesthetized and perfused-fixed by injecting
4% formaldehyde through the left cardiac ventricle.
Brains were removed, post-fixed in 4% formaldehyde
overnight and processed into paraffin. Coronal tissue
sections (7 μm thick) through the injection tract were
stained with H + E, Luxol Fast Blue (LFB) [5] or
immunostained.
For diaminobenzidine immunostaining, the sections
were unmasked in citrate, incubated with primary anti-
body (one hour, 25°C), biotinylated secondary antibody
(1:500, one hour, 25°C) and visualized using the VectastainHRP kit (Vector Labs, Peterborough, UK). We counter-
stained nuclei with haematoxylin. Primary antibodies
were rabbit anti-AQP4 (1:100), rabbit anti-glial fibrillary
acidic protein (GFAP, 1:200), mouse anti-NeuN (1:200),
(Millipore, Livingstone, UK), mouse anti-myelin basic
protein (MBP, 1:400, Leica, Newcastle, UK), mouse anti-
neurofilament-70 (1:600, DAKO, Ely, UK), rabbit anti-
C5b-9 (1:100, Abcam, Cambridge, UK) and rat anti-CD45
(1:200, BD Bioscience, Oxford, UK). Samples were then
incubated with the appropriate species biotinylated sec-
ondary antibody (1:500, Vector Laboratories). Immuno-
staining was visualized brown using the Vectastain
horseradish peroxidase kit (Vector Laboratories) followed
by diaminobenzidine/H2O2. Nuclei were counterstained
blue with haematoxylin.
For immunofluorescence staining, we used rabbit anti-
Ankyrin G (AnkG, InsightBio, Wembley, UK) or rabbit
anti-Contactin associated protein (Caspr) from Abcam
(1:200, 12 hours, 25°C) followed by Alexafluor-linked
anti-rabbit antibody (1:200, one hour, 25°C, Invitrogen,
Paisley, UK).
To determine MOG-IgG binding to mouse brain sec-
tions, brains were removed, immersed in 30% sucrose
overnight, embedded in OCT and cut into 7 μm sec-
tions. These were fixed in acetone and exposed to
IgGMOG(AdsHEK), IgGMOG(AdsMOG-HEK), IgGCON (1:100)
or MOG-IgG2b7 (1 mg/mL) ± rabbit anti-MOG (1:100,
InsightBio) for one hour at 25°C followed by Alexafluor-
linked anti-human ± anti-rabbit IgG (1:200, one hour,
25°C, Invitrogen) and DAPI.
Photomicrographs were taken using an Olympus BX-
51 microscope.
Data analysis
Coded photomicrographs were analysed with ImageJ
(v1.45S, NIH). Neurofilament immunoreactivity in the
injected hemisphere was quantified as mean staining in-
tensity minus background. AnkG and Caspr expression
was the number of fluorescent spots/mm2 in four photo-
micrographs, 90 μm × 67 μm, taken from the injected
hemisphere 0.5 mm from the needle tract. After sub-
tracting background, formatting images to 8-bit, adjust-
ing threshold, the ‘analyse particles’ function of Image J
was used. Spots < 0.01 μm2 were excluded as noise.
Statistics
Data are mean ± standard error. We used Student t-test
or ANOVA with Student-Newman-Keuls post-hoc ana-
lysis. Significance is P < 0.05*, 0.01**, 0.001***.
Results
Lesions induced by IgGMOG compared to IgGAQP4
IgGMOG + Chu caused brain edema at 24 hours, but by
seven days and two weeks the brain appeared normal
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at 24 hours, at seven days there was marked leukocyte
infiltration and by two weeks reactive gliosis (Figure 1A).
IgGMOG + Chu caused loss of Luxol Fast Blue (LFB)
staining at 24 hours, but this had reversed by two weeks,
while the IgGAQP4 + Chu – injected tissue showed in-
creased loss of LFB staining at seven days and only
partially recovered at two weeks (Figure 1B). The re-
cruitment of inflammatory cells also differed markedly
between the two preparations. IgGMOG + Chu did not
produce inflammation while IgGAQP4 + Chu caused in-
flammation at 24 hours (perivascular neutrophils) and
seven days (mostly macrophages) (Figure 1C).
We immunostained for two astrocyte markers, AQP4
and GFAP. Loss of AQP4 and GFAP was seen inFigure 1 Brain lesions caused by MOG-IgG and AQP4-IgG. Mice receiv
were killed at 24 hours (d1), seven days (d7) or two weeks (d14) and coron
Ed, edema; L, lumen; leuko, leukocytes; RG, reactive glia; wm, white matter.
LFB stain (area without LFB/ipsilateral hemispheric area) vs. days since injec
magnified below. Arrows, CD45+ cells; L, vessel lumen; mϕ, macrophages.
vs. days since injection. Mean ± SEM, 5 mice per group. P < 0.01**, 0.001***
(B, C d7 top), 20 μm (C d7 bottom).IgGAQP4 + Chu – injected brains (at 24 hours and seven
days) but IgGMOG + Chu did not reduce AQP4 and GFAP
(Figure 2). At two weeks there was marked gliosis (in-
creased AQP4 and GFAP) in brains injected with
IgGAQP4 + Chu, compared to little gliosis in brains that
received IgGMOG + Chu (Figure 2).
MOG-IgG binds mouse MOG and causes loss of LFB
staining
To confirm that IgGMOG binds mouse myelin, it was
applied to brain sections. IgGMOG bound the corpus
callosum; binding co-localized with a commercial anti-
MOG antibody (Figure 3A). IgGMOG adsorbed by incu-
bation with MOG-expressing human embryonic kidney
(MOG-HEK) cells until MOG-IgG became undetectableed IgGCON + Chu (purple), IgGMOG + Chu (green) or IgGAQP4 + Chu (blue),
al brain sections were cut through the injection site. A. H + E staining.
B. (Top) LFB staining. Red line, loss of LFB staining. (Bottom) % Loss of
tion. C. (Top) CD45 immunostain. Each boxed area in d7 top is shown
(Bottom) % CD45+ area (CD45+ area/ipsilateral hemispheric area)
(compared with each of the other two groups). Bar 50 μm (A), 1 mm
Figure 2 Effect of MOG-IgG and AQP4-IgG on astrocytes. Mice
received IgGCON + Chu (purple), IgGMOG + Chu (green) or IgGAQP4 +
Chu (blue), were killed at 24 hours (d1), seven days (d7) or two
weeks (d14) and coronal brain sections were cut through the
injection site. A. (Top) AQP4 immunostain. Arrows, perivascular
immunostain; red line, lesion border; ↑AQP4, area with high AQP4
(reactive astrocytes). (Bottom) % AQP4 loss (AQP4 immunonegative
area/ipsilateral hemispheric area) vs. days since injection. B. GFAP
immunostain. Arrows, GFAP+ processes; red line, lesion border;
↑GFAP, area with high GFAP (reactive astrocytes). Mean ± SEM, 5
mice per group. P < 0.01**, 0.001*** (compared with each of the
other two groups). Bar 50 μm (A, B).
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unlike IgGMOG adsorbed against untransfected HEK
cells (IgGMOG(AdsHEK)) (Figure 3B). To confirm that the
MOG-IgG was responsible for the loss of LFB staining,
the two adsorbed preparations were injected with Chu
and mice were killed at seven days. Loss of LFB staining
in the injected hemisphere was only found when
IgGMOG(AdsHEK) + Chu was used (Figure 3C).
MOG-IgG2B7 causes loss of LFB staining largely
independent of immune cells or complement activation
In case the amount of MOG-IgG in the patient prepara-
tions was insufficient to cause inflammatory cell infiltra-
tion, a large amount (20 μg) of the humanized anti-mouse
MOG-IgG2B7 was co-injected with Chu. At seven days,
MOG-IgG2B7 + Chu caused loss of LFB staining, but with-
out inflammatory cell infiltration (Figure 4A). At 24 hours
after injecting MOG-IgG2B7 + Chu there was faint C5b-9
immunoreactivity in white matter tracts suggesting slight
complement activation, whereas injection of a monoclonal
recombinant anti-AQP4 (AQP4-IgG53) + Chu caused strong
perivascular C5b-9 immunoreactivity (Figure 4B). More-
over, intracerebral injection of MOG-IgG2B7 without Chu
produced loss of LFB staining at 24 hours similar to
MOG-IgG2B7 + Chu (Figure 4C).
MOG-IgG causes reversible damage to myelinated axons
At two weeks there was marked neuronal loss in
IgGAQP4 + Chu lesions compared to little neuronal loss in
brains injected with IgGMOG + Chu (Figure 5A). We in-
vestigated the effect of IgGMOG + Chu on myelin and
axonal proteins including myelin basic protein (MBP),
neurofilament, ankyrin G (AnkG) and contactin associ-
ated protein (Caspr) (Figure 5B). MBP adheres adjacent
cytoplasmic faces of myelin together, neurofilament pro-
vides structural support for axons, AnkG clusters
voltage-gated Na+ channels at nodes of Ranvier [21] and
Caspr attaches paranodal myelin loops to the axons [22].
At 24 hours after IgGMOG + Chu injection, MBP expres-
sion appeared abnormal (Figure 5C) and there was sig-
nificant reduction in AnkG (Figure 5D) and Caspr
(Figure 5E) immunoreactivities. At two weeks, the
MOG-IgG + Chu – induced changes in MBP, AnkG and
Caspr had recovered and neurofilament expression was
normal (Figure 5F), indicating intact axons.
Discussion
Although there is growing interest in the potential
pathogenicity of MOG antibodies in NMO, the effects
of NMO MOG-IgG have not been explored in vivo.
Our results indicate that MOG-IgG directly damages
myelin. The detrimental effects of MOG-IgG markedly
differ from those of AQP4-IgG and are reversible (see
Table 1).
Figure 3 MOG-IgG binds mouse MOG and causes loss of LFB
staining. A. Mouse corpus callosum (CC) fluorescently immunostained
with IgGMOG (green) and anti-MOG (red). DAPI nuclear stain. B. CC
immunostained fluorescent red with IgGMOG, IgGMOG(AdsMOG-HEK),
MOG-IgG2B7 and IgGCON. DAPI nuclear stain. Insets – immunopositive
(DAB) gray matter neurons. C. Mouse brain injected with
IgGMOG(AdsHEK) + Chu or IgGMOG(AdsMOG-HEK) + Chu. (Top) LFB stained
sections at 24 hours. Red line, no LFB staining. (Bottom). Data summary.
5 mice per group. Mean ± SEM. P < 0.05*. Bar 10 μm (A insets), 50 μm
(A, B), 1 mm (C).
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age followed by leukocyte infiltration that entirely de-
pend on complement activation [5]. We showed that
recovery of myelin loss in AQP4-IgG lesions is limited,
with gliosis and neuronal death. This finding may ex-
plain why clinical recovery after AQP4-IgG NMO at-
tacks is often limited [7-9]. By contrast, MOG-IgG, as
examined here, damages myelin and axons temporarily,
with little complement activation, and no leukocyte infil-
tration. The myelin and axonal recovery and lack of
neuronal death mirror the reported good outcomes of
MOG-IgG NMO patients [10,11,15,16].
One study suggested that IgGMOG obtained from chil-
dren with demyelination does not bind mouse MOG
[23], but another study showed that human MOG-IgG
binds mouse MOG [24]. Our IgGMOG samples obtained
from adult NMO patients, and the anti-mouse MOG-
specific monoclonal antibody, both recognized mouse
MOG in frozen brain sections, and produced compar-
able LFB loss without inflammation. This discrepancy
may be due to differences in MOG-IgG levels and speci-
ficity or differences in MOG glycosylation state, which
plays a key role in MOG-IgG binding [24], between chil-
dren and adults.
The effects of MOG-IgG on cultured oligodendrocytes
have already been studied. MOG-IgG binds extracellular
epitopes on MOG [23] and can cause crosslinking [25]
and internalization [12] of MOG molecules and reversible
retraction of oligodendrocyte processes [25]. At high con-
centration, MOG-IgG causes complement-mediated lysis
of MOG-expressing cells [12]. Passive transfer of MOG-
IgG antibodies exacerbates CNS damage in experimental
autoimmune encephalomyelitis rodent models in which
cellular immunity is the predominant pathogenic mechan-
ism [26,27]. Using the intracerebral injection mouse
model, we have shown unequivocally that NMO MOG-
IgG directly damages myelin in vivo independent of pre-
existing cellular immunity and complement.
MOG-IgG changed MBP architecture and reduced ex-
pression of axonal proteins. Caspr and AnkG are required
for the integrity of the nodes of Ranvier and normal action
potential firing [21,22]. Mice that lack MBP have a
Figure 4 MOG-IgG2B7 causes loss of LFB staining largely
independent of immune cells or complement activation. A.
Adjacent sections stained with H + E and LFB at seven days after
injecting MOG-IgG2B7 + Chu. Green line shows loss of LFB staining.
Rectangles show sites of Sections. B. Mouse brain immunostaned for
C5b-9 at 24 hours after injection of IgGCON + Chu, IgGMOG + Chu, or
IgGAQP4 + Chu. Lu, lumen; wm, white matter. Weak (gray arrows) and
strong (black arrows) immunoreactivity. C. Loss of LFB staining at
24 hours after injection of MOG-IgG2B7, MOG-IgG2B7 + Chu, or
isotype control (CON-IgG2B4). 5 mice per group. Mean ± SEM.
P < 0.05*, < 0.01**. Bar 50 μm (A bottom right, B), 200 μm
(A bottom left), 1 mm (A top).
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zures [28], mice that lack Caspr have severe motor paresis
[22] whereas mice lacking cerebellar ankG develop pro-
gressive ataxia [21]. Therefore, the altered MBP expression
and reduced Caspr and AnkG expression produced by
MOG-IgG are predicted to produce a neurological deficit
if the NMO lesion is in an eloquent region of the CNS.
Unlike AQP4-IgG, MOG-IgG did not produce axonal dis-
integration or neuronal death. Given the 96% homology
between mouse and human MOG [14], our findings raise
the possibility that MOG-IgG may also cause similar re-
versible lesions in the human CNS.
MOG-IgG has been reported in other non-NMO dis-
eases including multiple sclerosis, acute disseminated
encephalomyelitis and even some normal subjects [29].
Does MOG-IgG from these non-NMO subjects also
cause the same reversible CNS changes, as described
here for NMO MOG-IgG? This question is difficult to
answer at present because of the variety of assays used
to detect MOG-IgG. For example, the assay used here,
which employs C-terminal truncated rather than full-
length MOG, did not detect MOG-IgG in adult multiple
sclerosis patients and normal individuals [11], which
suggests that different assays detect different subpopula-
tions of MOG-IgG. It is important to first standardize
the assays before determining which subpopulations of
MOG-IgG can cause CNS damage and in which
diseases.
The mechanism of MOG-IgG-induced myelin damage
in vivo is unknown. Our data show that MOG-IgG –
mediated myelin damage is a direct effect of MOG-IgG
and that complement activation is not necessary. MOG-
IgG binding may cause MOG conformational changes or
internalization that disrupts the myelin structure and
secondarily alters axonal protein expression. To explain
the lack of complement involvement, we hypothesize
that, after MOG-IgG binding, MOG might not aggregate
(because of its low abundance) or MOG might become
internalized (thus prohibiting C1q activation). The full
recovery within two weeks of the MOG-IgG-induced
LFB, MBP, ankG and Caspr changes suggests that
MOG-IgG does not kill the oligodendrocytes, but causes
a reversible damage.
Our findings raise the possibility that MOG-IgG con-
tributes to pathology in some NMO patients. If MOG-
IgG is pathogenic, antibody depletion (plasmapheresis)
or suppression with steroids should be effective, as in-
deed appears to be the case [10,11,15,16]. Conversely,
some of the newly proposed therapies for AQP4-IgG
NMO, such as sivelestat for inhibiting neutrophils [17],
or eculizumab for inhibiting complement [30], are less
likely to be needed in MOG-IgG NMO. Examining le-
sions from MOG-IgG NMO patients may help elucidate
the pathogenicity of MOG-IgG in the human CNS.
Figure 5 Effect of MOG-IgG on neurons. A. (Left) NeuN immunoreactivity at 2w. Area lacking neurons outlined red. (Right) % NeuN loss (NeuN
immunonegative area/ipsilatral hemispheric area). B. Node of Ranvier: ankG, ankyrin G; Caspr, contactin associated protein; MBP, myelin basic
protein; MOG, myelin oligodendrocyte glycoprotein; Nav, voltage-gated Na
+ channel; Nfil, neurofilament. C. MBP immunoreactivity. (Top) Normal
and abnormal white matter tracts. (Bottom) % abnormal tracts in injected hemisphere. D. Caspr immunoreactivity within white matter tracts. (Top)
Hemispheres injected with IgGCON + Chu and IgGMOG + Chu. (Bottom) Data summary. E. AnkG immunoreactivity within white matter tracts. (Top)
Hemispheres injected with IgGCON + Chu and IgGMOG + Chu. (Bottom) Data summary. F. Nfil immunoreactivity. (Top) Hemispheres injected with
IgGCON + Chu and IgGMOG + Chu. Arrowheads: white matter tracts. (Bottom) Data summary (a.u. arbitrary units). 5 mice per group. P <0.05*, <0.01**.
Bar 0.5 mm (A), 20 μm (C), 10 μm (D, E), 50 μm (F).
Saadoun et al. Acta Neuropathologica Communications 2014, 2:35 Page 7 of 9
http://www.actaneurocomms.org/content/2/1/35Conclusions
MOG-IgG obtained from neuromyelitis optica patients
causes myelin changes and alters the expression of axonal
proteins when injected in mouse brain. These effects are
not associated with inflammatory cell infiltration, are largely
independent of complement and recover within two weeks.
AQP4-IgG obtained from neuromyelitis optica patients
causes complement-mediated myelin loss, inflammatoryTable 1 Comparison of MOG-IgG with AQP4-IgG lesions in mo
Characteristic MOG-IgG
Target cell Oligodendrocyte (myelin)
Lesion onset Within hours of exposure to MOG-Ig
Effect on astrocytes No major effect (normal AQP4 and G
Effect on neurons No major effect
Effect on oligodendrocytes Change in myelin (loss of LFB)
Effect on axons Myelin (transient change in MBP)
Intact axons (normal nfil)
Node of Ranvier (transient change in
Inflammatory cell infiltration No
Complement activation Slight (in white matter tracts)
Not required for lesion to develop
Recovery Yes, within 2 weeks
β-APP, beta amyloid precursor protein; FJ-C, fluorojade C; GFAP, glial fibrillary acidic pr
marker; nfil, neurofilament.cell infiltration, neuronal and astrocyte death with limited
recovery at two weeks. These findings raise the possibility
that MOG-IgG contributes to pathology in some neuromy-
elitis optica patients.
Availability of supporting data
No supporting data.use brain
AQP4-IgG
Astrocyte (foot process)
G Within hours of exposure to AQP4-IgG
FAP) Astrocyte death (loss of AQP4 and GFAP)
Neuronal death (loss of NeuN, FJ-C staining [5])
Loss of myelin (loss of LFB)
Permanent loss of myelin




Essential for lesion to develop
No, pan-necrosis followed by glial scarring
otein; LFB, Luxol fast blue; MBP, myelin basic protein; NeuN, neuronal nuclear
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AnkG: Ankyrin G; AQP4: Aquaporin-4; AQP4-IgG: Aquaporin-4 IgG found in
most neuromyelitis optica patients; C5b-9: Complement membrane attack
complex; Caspr: Contactin associated protein; Chu: Human complement;
CNS: Central nervous system; CON-IgG2B4: Monoclonal (2B4) control IgG;
GFAP: Glial fibrillary acidic protein; H + E: Hematoxylin and eosin; IgGAQP4:
IgG fraction of serum from neuromyelitis optica patients containing AQP4-IgG;
IgGCON: IgG fraction of serum from normal subjects; IgGMOG: IgG fraction of
serum from neuromyelitis optica patients containing MOG-IgG; IgGMOG(AdsHEK):
IgGMOG adsorbed against untransfected HEK cells; IgGMOG(AdsMOG-HEK):
IgGMOG adsorbed against MOG-HEK to deplete MOG-IgG; LFB: Luxol fast blue;
MBP: Myelin basic protein; MOG: Myelin oligodendrocyte glycoprotein;
MOG-IgG2B7: Chimeric anti-mouse MOG recombinant IgG in which the
constant mouse regions of the heavy and light chains were substituted with
the human IgG1 constant regions, CH and Cκ.; NeuN: Neuronal nuclei;
Nfil: Neurofilament; NMO: Neuromyelitis optica.
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